Candel Therapeutics (CADL)

Executive Summary

Candel Therapeutics (NASDAQ: CADL) is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies for cancer. Its two lead platforms are CAN-2409, a replication-deficient adenovirus with prodrug activation, and CAN-3110, a modified herpes simplex virus (HSV) construct. CAN-2409 is being evaluated in Phase 2 and Phase 3 trials across multiple solid tumor indications, including non-small cell lung cancer (NSCLC), prostate cancer, and pancreatic cancer. CAN-3110 is in clinical development for recurrent high-grade glioma. Both therapies aim to selectively infect and lyse tumor cells while stimulating a systemic anti-tumor immune response. The company's near-term value hinges on clinical data readouts and regulatory milestones. Key upcoming catalysts include Phase 2 data for CAN-2409 in NSCLC and interim results for CAN-3110 in glioma. Positive efficacy and safety data could significantly enhance the probability of advancing to registrational trials or partnership opportunities. However, given the early-stage nature and competitive landscape in oncolytic virus therapy, execution and differentiation remain critical. Candel has a modest market capitalization, suggesting potential upside if trials succeed, but also high risk typical of clinical-stage biotech.

Upcoming Catalysts (preview)

• H2 2026CAN-2409 Phase 2 data readout in non-small cell lung cancer50% success
• H2 2026CAN-3110 Phase 2 interim efficacy data in recurrent high-grade glioma40% success
• TBDPotential partnership or licensing deal for CAN-2409 or CAN-311030% success